Absci (ABSI) Stock Forecast, Price Target & Predictions
ABSI Stock Forecast
Absci stock forecast is as follows: an average price target of $6.00 (represents a 100.67% upside from ABSI’s last price of $2.99) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
ABSI Price Target
The average price target for Absci (ABSI) is $6.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 100.67% upside from ABSI's last price of $2.99.
ABSI Analyst Ratings
According to 4 Wall Street analysts, Absci's rating consensus is 'Buy'. The analyst rating breakdown for ABSI stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Absci Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Mar 21, 2024 | Daniel Arias | Stifel Nicolaus | $6.00 | $5.28 | 13.64% | 100.67% |
The latest Absci stock forecast, released on Mar 21, 2024 by Daniel Arias from Stifel Nicolaus, set a price target of $6.00, which represents a 13.64% increase from the stock price at the time of the forecast ($5.28), and a 100.67% increase from ABSI last price ($2.99).
Absci Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $6.00 |
| Last Closing Price | $2.99 | $2.99 | $2.99 |
| Upside/Downside | -100.00% | -100.00% | 100.67% |
In the current month, the average price target of Absci stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Absci's last price of $2.99. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 01, 2024 | Guggenheim | Buy | Initialise | |
| Aug 15, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jul 03, 2024 | Morgan Stanley | Overweight | Initialise | |
| Jun 28, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 15, 2024 | Truist Financial | Sector Outperform | Sector Outperform | Hold |
| Mar 22, 2024 | Scotiabank | Sector Outperform | Sector Outperform | Hold |
| Jan 08, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 12, 2022 | Cowen & Co. | Outperform | Upgrade |
Absci's last stock rating was published by Guggenheim on Oct 01, 2024. The company Initialise its ABSI rating from "null" to "Buy".
Absci Financial Forecast
Absci Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $744.00K | $3.37M | $1.27M | $1.56M | $2.37M | $1.00M | $819.00K | $1.45M | $1.54M | $728.00K |
| Avg Forecast | $9.30M | $9.20M | $4.00M | $5.40M | $8.50M | $12.65M | $6.65M | $6.55M | $1.80M | $1.75M | $1.91M | $2.10M | $900.00K | $3.00M | $2.44M | $2.25M | $4.73M | $1.87M | $1.62M | $1.79M | $1.69M | $2.01M | $1.75M |
| High Forecast | $11.48M | $11.35M | $4.94M | $6.66M | $10.49M | $15.61M | $8.21M | $8.08M | $2.50M | $2.16M | $1.91M | $2.59M | $1.18M | $3.70M | $3.01M | $2.77M | $5.83M | $1.87M | $1.62M | $1.79M | $1.69M | $2.01M | $1.75M |
| Low Forecast | $7.04M | $6.97M | $3.03M | $4.09M | $6.44M | $9.58M | $5.03M | $4.96M | $1.37M | $1.33M | $1.91M | $1.59M | $154.28K | $2.27M | $1.84M | $1.70M | $3.58M | $1.87M | $1.62M | $1.79M | $1.69M | $2.01M | $1.75M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.25% | 1.38% | 0.56% | 0.33% | 1.26% | 0.62% | 0.46% | 0.86% | 0.77% | 0.42% |
Absci's average Quarter revenue forecast for Dec 23 based on 4 analysts is $900.00K, with a low forecast of $154.28K, and a high forecast of $1.18M. ABSI's average Quarter revenue forecast represents a 20.97% increase compared to the company's last Quarter revenue of $744.00K (Sep 23).
Absci EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-18.74M | $-16.57M | $-19.52M | $-16.10M | $-23.89M | $-25.60M | $-25.77M | $-30.17M | $-22.35M | $-43.60M |
| Avg Forecast | $-9.30M | $-9.20M | $-4.00M | $-5.40M | $-8.50M | $-12.65M | $-6.65M | $-6.55M | $-1.80M | $-1.75M | $-1.91M | $-2.10M | $-900.00K | $-3.00M | $-2.44M | $-2.25M | $-4.73M | $-1.87M | $-1.62M | $-22.22M | $-1.69M | $-14.90M | $-1.75M |
| High Forecast | $-7.04M | $-6.97M | $-3.03M | $-4.09M | $-6.44M | $-9.58M | $-5.03M | $-4.96M | $-1.37M | $-1.33M | $-1.91M | $-1.59M | $-154.28K | $-2.27M | $-1.84M | $-1.70M | $-3.58M | $-1.87M | $-1.62M | $-17.77M | $-1.69M | $-11.92M | $-1.75M |
| Low Forecast | $-11.48M | $-11.35M | $-4.94M | $-6.66M | $-10.49M | $-15.61M | $-8.21M | $-8.08M | $-2.50M | $-2.16M | $-1.91M | $-2.59M | $-1.18M | $-3.70M | $-3.01M | $-2.77M | $-5.83M | $-1.87M | $-1.62M | $-26.66M | $-1.69M | $-17.88M | $-1.75M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.25% | 6.80% | 8.69% | 3.40% | 12.75% | 15.79% | 1.16% | 17.82% | 1.50% | 24.91% |
undefined analysts predict ABSI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Absci's previous annual EBITDA (undefined) of $NaN.
Absci Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-21.99M | $-41.67M | $-23.36M | $-19.47M | $-27.26M | $-28.68M | $-29.49M | $-25.17M | $-23.63M | $-41.20M |
| Avg Forecast | - | - | - | - | $-16.47M | $-11.93M | $-16.47M | $-17.61M | $-24.87M | $-22.05M | $-20.61M | $-24.05M | $-24.14M | $-26.13M | $-27.04M | $-26.35M | $-28.58M | $-31.96M | $-35.25M | $-25.43M | $-27.89M | $-15.76M | $-19.36M |
| High Forecast | - | - | - | - | $-11.27M | $-8.16M | $-11.27M | $-12.05M | $-23.79M | $-15.09M | $-14.10M | $-16.45M | $-22.04M | $-17.88M | $-18.50M | $-18.03M | $-19.55M | $-31.96M | $-35.25M | $-20.34M | $-27.89M | $-12.60M | $-19.36M |
| Low Forecast | - | - | - | - | $-21.49M | $-15.56M | $-21.49M | $-22.97M | $-27.03M | $-28.76M | $-26.88M | $-31.36M | $-28.34M | $-34.08M | $-35.26M | $-34.37M | $-37.27M | $-31.96M | $-35.25M | $-30.51M | $-27.89M | $-18.91M | $-19.36M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.84% | 1.54% | 0.89% | 0.68% | 0.85% | 0.81% | 1.16% | 0.90% | 1.50% | 2.13% |
Absci's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ABSI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Absci SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $9.51M | $9.41M | $9.59M | $7.75M | $11.41M | $10.51M | $10.89M | $9.18M | $9.73M | $5.18M |
| Avg Forecast | $41.95M | $41.50M | $18.04M | $24.36M | $38.34M | $57.06M | $29.99M | $29.54M | $8.12M | $7.91M | $8.60M | $9.47M | $4.06M | $13.53M | $10.99M | $10.13M | $21.33M | $8.45M | $7.31M | $8.09M | $7.64M | $9.05M | $7.90M |
| High Forecast | $51.76M | $51.21M | $22.26M | $30.06M | $47.31M | $70.41M | $37.01M | $36.46M | $11.28M | $9.76M | $8.60M | $11.68M | $5.34M | $16.70M | $13.56M | $12.51M | $26.32M | $8.45M | $7.31M | $8.09M | $7.64M | $9.05M | $7.90M |
| Low Forecast | $31.76M | $31.42M | $13.66M | $18.44M | $29.03M | $43.20M | $22.71M | $22.37M | $6.19M | $5.99M | $8.60M | $7.17M | $695.89K | $10.24M | $8.32M | $7.67M | $16.15M | $8.45M | $7.31M | $8.09M | $7.64M | $9.05M | $7.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.70% | 0.86% | 0.95% | 0.36% | 1.35% | 1.44% | 1.35% | 1.20% | 1.08% | 0.66% |
Absci's average Quarter SG&A projection for Dec 23 is $4.06M, based on 4 Wall Street analysts, with a range of $695.89K to $5.34M. The forecast indicates a -57.29% fall compared to ABSI last annual SG&A of $9.51M (Sep 23).
Absci EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.24 | $-0.45 | $-0.26 | $-0.21 | $-0.30 | $-0.32 | $-0.33 | $-0.28 | $-0.33 | $-0.47 |
| Avg Forecast | - | - | - | - | $-0.14 | $-0.10 | $-0.14 | $-0.15 | $-0.22 | $-0.19 | $-0.18 | $-0.21 | $-0.21 | $-0.23 | $-0.24 | $-0.23 | $-0.25 | $-0.28 | $-0.31 | $-0.29 | $-0.25 | $-0.20 | $-0.17 |
| High Forecast | - | - | - | - | $-0.10 | $-0.07 | $-0.10 | $-0.11 | $-0.21 | $-0.13 | $-0.12 | $-0.14 | $-0.19 | $-0.16 | $-0.16 | $-0.16 | $-0.17 | $-0.28 | $-0.31 | $-0.29 | $-0.25 | $-0.20 | $-0.17 |
| Low Forecast | - | - | - | - | $-0.19 | $-0.14 | $-0.19 | $-0.20 | $-0.24 | $-0.25 | $-0.24 | $-0.28 | $-0.25 | $-0.30 | $-0.31 | $-0.30 | $-0.33 | $-0.28 | $-0.31 | $-0.29 | $-0.25 | $-0.20 | $-0.17 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 1.89% | 1.12% | 0.83% | 1.06% | 1.03% | 1.14% | 1.13% | 1.63% | 2.73% |
According to undefined Wall Street analysts, Absci's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ABSI previous annual EPS of $NaN (undefined).
Absci Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.52 | $70.00 | 13361.54% | Buy |
| ELEV | Elevation Oncology | $0.67 | $9.00 | 1243.28% | Buy |
| INZY | Inozyme Pharma | $2.94 | $16.00 | 444.22% | Buy |
| AFMD | Affimed | $1.51 | $7.50 | 396.69% | Buy |
| XFOR | X4 Pharmaceuticals | $0.74 | $3.67 | 395.95% | Buy |
| SANA | Sana Bio | $1.91 | $8.00 | 318.85% | Buy |
| RLAY | Relay Therapeutics | $4.50 | $18.00 | 300.00% | Buy |
| ZURA | Zura Bio | $2.51 | $10.00 | 298.41% | Buy |
| ABOS | Acumen Pharmaceuticals | $1.96 | $7.00 | 257.14% | Buy |
| DTIL | Precision BioSciences | $4.58 | $15.50 | 238.43% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| ABSI | Absci | $3.33 | $6.00 | 80.18% | Buy |
| CRBU | Caribou Biosciences | $1.94 | $3.00 | 54.64% | Buy |
| RXRX | Recursion Pharmaceuticals | $7.12 | $9.67 | 35.81% | Hold |